Introduction
In the treatment of epilepsy patients the relatively frequent occurrence of depression and anxiety often go unnoticed and therefore untreated [1] [2] [3] . In order to discover depression in epilepsy patients, the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) has been developed [4] . NDDI-E has been translated from English to other languages and validated as a screening tool for depression in epilepsy patients [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Recently, we published a Danish translation of NDDI-E [16] . The first purpose of the present study was to validate the Danish NDDI-E.
WHO-5 is a questionnaire with five positive statements, which measure mental well-being in the past two weeks [17] . WHO-5 has a value between 0 and 100. In a population study WHO-5 was in average 70, whereas depressive patients had a mean score of about 30 [17] . The second purpose of the present study was to examine WHO-5 as a screening test for depression and compare it with NDDI-E in epilepsy patients.
Anxiety, like depression, is also a relatively frequent companion of epilepsy [3] , but detection of anxiety may be more difficult in epilepsy patients because no epilepsy specific inventory for anxiety exists. Furthermore, there are several different anxiety disorders including panic disorder, agoraphobia, social phobia, and generalized anxiety. The third purpose of our study was to investigate whether WHO-5 or NDDI-E could be used in the detection of anxiety disorders in patients with epilepsy.
The fourth and final purpose of the study was to investigate if a combination of NDDI-E and WHO-5 would be better than either test alone in the identification of both depression and anxiety disorders in epilepsy patients.
Methods

Subjects
Adult patients with epilepsy treated at the epilepsy outpatient clinic, Department of Neurology, University Hospital of North Zealand, Hillerød, were included from October 1st 2013 to April 30th 2015. The inclusion criteria were as follows: age 18 years or above, diagnosis of epilepsy according to criteria by the International League Against Epilepsy, MRI or CT scan of the brain, EEG, treatment with at least one antiepileptic drug in a constant dose in the previous month, and the ability to read and speak Danish. Exclusion criteria were severe medical or psychiatric comorbidity and inability to read and/or speak Danish.
Flow of patients
All patients received oral and written information. After informed consent to participate in the study, patients were given the following self-report inventories:
Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) World Health Organization Well-being Index (WHO-5) Major Depression Inventory (MDI) Anxiety Symptom Scale (ASS)
The Mini International Neuropsychiatric Interview version 5.0.0 (MINI)
The patients included in the study returned to the outpatient clinic for a focused neuropsychiatric interview. A Danish version of the Mini International Neuropsychiatric Interview version 5.0.0 (MINI) was used. MINI is a validated interviewer-administered, structured, diagnostic psychiatric interview for DSM-IV [18] . We used MINI as the gold standard for current psychiatric diagnosis. MINI was carried out before examining the self-report inventories which the patients filled out at home and brought to the interview. Patients, who were diagnosed with a psychiatric disorder, were offered treatment according to local practice.
The Neurological Disorder Depression Inventory for Epilepsy (NDDI-E)
This screening tool for depression was developed for use specifically in patients with epilepsy [4] . It consists of six statements about the past two weeks that are scored between 1 (never) and 4 (always/often), with a minimum score of 6 and maximum of 24. In the original version, a score above 15 has been shown to have high predictive value for major depression [4] . Recently, we have published a translation of NDDI-E to Danish [16] .
The World Health Organization Well-being Index (WHO-5)
The WHO-5 consists of five items. Each item is rated on a 6-point scale from 0 to 5. The score ranges from 0 to 25. The percentage value is calculated by multiplying the score by 4 and thus obtaining a scale from 0 (worst) to 100 (best). A percentage score below 50 is interpreted as indicating risk of depression and anxiety [17, 19] .
The Major Depression Inventory (MDI)
This scale contains the items that cover the ICD-10 symptoms of depression. We used the MDI as a diagnostic tool requiring core symptoms of depression to be present most of the time for the past two weeks [17] .
The Anxiety Symptom Scale (ASS)
The ASS consists of 10 items. The presence of the items on levels 0-5 in the previous 14 days is assessed. The ASS was considered positive when item 10, the impact on daily activities, had a score of three or more, and there was a score on the top three symptoms which are the actual anxiety symptoms [17] .
Statistics
We used SAS 9.3. Continuous data were compared using unpaired t-tests. The Chi-square test was used for categorical data and Fisher's exact test if the cells had a frequency of five or less. P < 0.05 was considered statistically significant. Excel was used to calculate sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristic (ROC) curves and area under the curve (AUC).
Ethics
The study was approved by the Ethical Committee of the Capital Region of Denmark (H-3-2012-086, anm. no. 39222). All patients gave their written informed consent prior to inclusion in the study.
Results
Basic characteristics
A total of 124 patients were included in this study. Of these 21 patients (17%) were diagnosed with depression (n = 6), anxiety (n = 8) or both in combination (n = 7). The group of patients with an anxiety disorder included 3 patients with generalized anxiety and 12 patients with one or two of the disorders panic disorder, agoraphobia, and social phobia. Other MINI-verified diagnosis found were dysthymia (n = 5), alcoholism (n = 9), dissocial personality disorder (n = 1), obsessive compulsive disorder (n = 1) and current mania (n = 1). In Table 1 the basic data are shown. The ideal test has a sensitivity of 1 and specificity of 1, which means that the point on the ROC curve closest to the top left corner is the best possible combination of sensitivity and specificity. In the original English version of NDDI-E [4] , a threshold of 15 was found to be optimal. In the present study 18 patients scored above 15.
Screening for depression
However, the best combination of sensitivity, specificity, PPV and NPV was found with a cut-off value of >13 for NDDI-E and <50 for WHO-5. 29 patients had a score below 50 in WHO-5. With a cut-off value > 13, the NDDI-E outweighs the WHO-5 (<50) with higher sensitivity and slightly higher PPV and NPV, see Table 2 . The NDDI-E cut-off value > 13 was also used in the subsequent tables. Table 2 also shows the sensitivity, specificity, PPV and NPV for MDI. The sensitivity of MDI as a screening tool for depression in epilepsy patients is low (0.308). Depression was indicated by MDI in 7 patients, but only 4 of these were true positive. AUC for NDDI-E and WHO-5 were almost identical (AUC NDDI-E = 0.867, AUC WHO-5 = 0.862), but somewhat lower than the AUC under the curves for depression in Fig. 1 . The best combination of sensitivity, specificity, PPV and NPV for NDDI-E was found with a cut-off value of >12, and for WHO-5 < 50. With these cut-off values, WHO-5 outweighs the NDDI-E with higher specificity and PPV (see Table 3 ). ASS has a very low sensitivity (0.200) as a screening test for anxiety in epilepsy patients. MDI indicated anxiety in 8 patients.
Screening for anxiety disorders
Combined screening for depression and anxiety disorders
By screening the 124 epilepsy patients for the presence of depression or any anxiety disorder or both by NDDI-E > 13 combined with WHO-5 < 50, we identified 20 of the 21 patients with depression, anxiety or both. Therefore, Table 4 shows a sensitivity of 0.95. The specificity is somewhat lower, 0. 20 true positives, the PPV is 0.49. The NPV is very high, because only 1 of 83 negative screens was false negative.
Discussion
The most important finding in the present study was that it was possible to identify 95% of all epilepsy patients with depression or anxiety or both by combining NDDI-E and WHO-5. To our knowledge, this is the first published validated combined screening for depression and anxiety in epilepsy patients. We believe that it is also the first validation of WHO-5 as screening test for depression and anxiety in epilepsy patients.
In the original publication of NDDI-E, a score above 15 was found to be optimal for the identification of depression in epilepsy patients [4] . Subsequently, NDDI-E has been translated from English into Portugese, Italian, Spanish, Japanese, German, Korean, Greek, Arabic, French, Chinese, and Danish [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . By the validation, the optimal threshold for detection of depression in epilepsy patients was NDDI-E above 15 in six, above 11 in one (Korean), above 13 in two, above 14 in one, and above 16 in one of the other studies. We have now validated the Danish version of NDDI-E and found that a threshold of NDDI-E above 13 is optimal. It is remarkable that six short and negative statements can be used in a reliable and valid way to identify depression in epilepsy patients in so many languages and cultures across the world. The reason for the apparent global utility of NDDI-E must be the global occurrence of depression in epilepsy patients [3] and the initial development of NDDI-E, which excluded confounding factors, mainly side effects of antiepileptic drugs and cognitive consequences of epilepsy [4] . When interpreting the positive and negative predictive values of NDDI-E and other tests it should be kept in mind that PPV and NPV do not have universal validity but depend on the prevalence of the disease. In the present study, the prevalence of depression was 10.5%. Consequently, the values of PPV and NPV in Table 2 are valid for a Danish epilepsy population with a prevalence of depression of 10.5%.
WHO-5 is the five item World Health Organization Well-Being Index, which was published first in 1998 and reviewed very recently [19] . WHO-5 is a sensitive and specific screening tool for depression, and it is applicable across many study fields [19] . However, the present study is to our knowledge the first published study on WHO-5 as a screening tool for depression in epilepsy patients. Generally, WHO-5 which may vary from 0 to 100, indicates risk of depression with a score below 50, and patients with depression and without epilepsy were found to have an average WHO-5 score of around 32, whereas persons who are not diagnosed with a mental disorder have average WHO-5 around 66 [17] . In the present study epilepsy patients with depression had an average WHO-5 score of 24, and the group of epilepsy patients without a psychiatric diagnosis had an average WHO-5 of 72.6. Thus, the WHO-5 values for epilepsy patients with and without depression match the respective values for persons without epilepsy.
Furthermore, our results show that WHO-5 with a cut off score below 50 is almost as good as NDDI-E with a cut off score above 13 in the detection of depression in epilepsy patients. This is remarkable, since NDDI-E consists of six negative statements which directly indicate depression, whereas WHO-5 consists of five positive statements indicating psychological well-being. Although many factors could potentially reduce the psychological well-being of an individual as measured by WHO-5, depressions reduce WHO-5 more than any other factor [17] .
Depression and anxiety often coexist in patients with epilepsyand also in persons without epilepsy [3] . The question is how to identify patients with an anxiety disorder without depression. Using MINI we identified 15 epilepsy patients with anxiety. The majority had panic attack disorder, agoraphobia, social phobia or a combination of two of these anxiety disorders, and a few patients had generalized anxiety disorder. Recently, the inventory GAD-7 assessing generalized anxiety disorder has been found useful in epilepsy patients with this anxiety disorder [20] . However, to our knowledge the remaining types of anxiety have not been identified with specific inventories in epilepsy patients. Furthermore, epilepsy patients who are not seizure free typically fear new seizures and their consequences. The influence of this understandable fear on the outcome of screening tests for anxiety remains to be studied scientifically.
In the present study, looking at the 15 patients with different anxiety disorders NDDI-E with a threshold above 12 yielded values for sensitivity, specificity, and PPV lower than NDDI-E > 13 values for depression. Thus, NDDI-E is better in identifying depression than anxiety.
WHO-5 was better than NDDI-E in detecting anxiety in epilepsy patients. In anxiety patients without epilepsy WHO-5 has been found to be in average around 45 [17] . The epilepsy patients with anxiety in the present study had an almost identical average . Setting the screening score of WHO-5 to values below 50 will therefore enable the identification of patients with anxiety disorder.
The most important result of our study is that a combination of NDDI-E with at cut off score above 13 and WHO-5 below 50 will correctly identify 95% of the epilepsy patients who suffer from depression, anxiety, or both. A NPV of 0.99 means a risk of only 1% of depression or anxiety in patients with a negative screening result of the two tests. Since both NDDI-E and WHO-5 are short and simple, they could be filled out by the patient in the waiting room and assessed quickly by the physician at the epilepsy control in the outpatient clinic. If the screening indicates depression or anxiety, a MINI or some other diagnostic interview should be carried out to set the diagnosis. Our results show that the combined use of WHO-5 and NDDI-E led to identification of 21 patients (out of 124) who did not fulfill the criteria for depression or anxiety disorder. These 17% were false positives. We find this acceptable, because the diagnostic procedure is harmless to the patient, the extra time spent on MINI is modest, and most of all because the 20 of the 21 epilepsy patients suffering from depression and/or anxiety will be identified systematically, so they can be offered treatment. Furthermore, we suspect that the false positives are in increased risk of depression and anxiety and should be followed more closely. Future controlled studies of treatment of depression and anxiety in epilepsy patients could use the approach for patient identification presented above. MDI and ASS turned out to be too insensitive in epilepsy patients for identification of depression and anxiety, respectively. The explanation is most likely, that only few epilepsy patients have severe depression and anxiety. We found in our previous study using Hamilton's depression and anxiety scales that the diagnosed depressions and anxiety disorders in epilepsy patients were light or moderate [16] .
In conclusion, the present study shows that the Danish NDDI-E with a cut off score above 13 is a valid tool for identification of depression in epilepsy patients. WHO-5 with a cut off score below 50 is almost equally good. With a WHO-5 cut off score below 50 it is possible to identify the majority of epilepsy patients with anxiety. Consequently, we recommend the combined use of NDDI-E and WHO-5 for clinical screening of epilepsy patients for depression and anxiety.
Conflict of interest
We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. We have no conflicts of interest.
